Live In Play®
Updated: 19-Sep-24 08:04 ET
TAK:  Takeda to present additional clinical trial study data highlighting the impact of Orexin agonist TAK-861 on the burden of narcolepsy at Sleep Europe 2024  (14.82)
Presentations Include New Data from the TAK-861-2001 Phase 2b Trial in Narcolepsy Type 1 Highlighting Impact on Daily Functioning Including Cognition and Sleep Quality...
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.